Buy Rating Affirmed for Longeveron on Favorable Lomecel-B Regulatory Outlook and Trial Progress
H.C. Wainwright Maintains Longeveron(LGVN.US) With Buy Rating, Maintains Target Price $10
Maxim Group Maintains Longeveron(LGVN.US) With Buy Rating, Cuts Target Price to $6
Longeveron Analyst Ratings
Maxim Group Maintains Longeveron(LGVN.US) With Buy Rating, Cuts Target Price to $6
H.C. Wainwright Maintains Longeveron(LGVN.US) With Buy Rating, Maintains Target Price $10
Buy Rating Reaffirmed for Longeveron on Strong Clinical Trial Prospects and Regulatory Advantages
Longeveron Analyst Ratings
H.C. Wainwright Maintains Longeveron(LGVN.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright Maintains Longeveron(LGVN.US) With Buy Rating, Cuts Target Price to $10
Buy Rating Affirmed for Longeveron as Lomecel-B Shows Promise in Clinical Trials and Gains FDA Designations
Longeveron Analyst Ratings
Longeveron Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Longeveron (LGVN) and EDAP TMS (EDAP)
Longeveron Analyst Ratings
Analysts' Top Healthcare Picks: Longeveron (LGVN), Optinose (OPTN)
Longeveron (LGVN) Receives a Buy From Maxim Group
Buy Rating Affirmed: Longeveron's Intellectual Property and Pipeline Progress Signal Market Growth
Buy Rating Affirmed for Longeveron on Promising CLEAR MIND Trial Results and Strong Lomecel-B Potential
HC Wainwright Initiates Longeveron With Buy Rating, Price Target Is $6
No Data
No Data